Special Phage Holdings wins NSW commercialisation award

Crunching the numbers from multivariate statistics sounds a rather dry topic to wet lab specialists, but a group of CSIRO researchers has taken a rather philosophical approach to managing the data mountain.

Cell therapy company CyGenics (ASX:CYN) has taken a 51 per cent controlling equity interest in cord blood stem cell banking business BioCell.

A new report on ASX-listed life sciences companies by PricewaterhouseCoopers shows that the sector has posted its worst quarterly performance in three years.

Pfizer Australia has hired cryogenic storage company Cryosite (ASX:CTE) to handle storage of its clinical trial drugs in Australia, and Cryosite CEO Gordon Milliken has pointed to a growing trend for big pharma and international biotechs to outsource the storage and logistics of their newest drugs to local service providers.

Multinational pharma Bristol-Myers Squibb has engaged Sydney-based cryogenic-storage company Cryosite (ASX:CTE) to manage its clinical trial supply logistics in Australia and New Zealand.

Sydney-based cryogenic storage company Cryosite (ASX: CTE) has entered into an agreement with Melbourne's Peter MacCallum Cancer Centre to provide long term storage of patients' blood stem cells.

Private cord blood storage service Cryosite has said it now does not expect to have to go through another round of fund-raising to achieve profitability.

Australia's first for-profit tissue banking service company, Cryosite, listed on the ASX today (May 9).

Cryogenic storage of umbilical cord blood has been given the thumbs up by Australian investors, with today's announcement that Cryosite's IPO closed early and oversubscribed.

The latest Deloitte index of companies on the Australian Stock Exchange's Healthcare and Biotechnology Index has painted a picture of increasing investor confidence in smaller stocks.